Clinical trial
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
NCT00498914 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00498914 |
|---|---|
| Title | Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects |
| Official title | A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large-Cell, Diffuse, B-Cell Refractory |
| Intervention type | Drug |
| Interventions | YM155 |
| Enrollment | 41 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jul 11, 2007 |
| Last update posted | Sep 4, 2015 |
| Countries | Canada, France, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: